WO2000062736A3 - Oligonucleotide antisens a faible teneur en adenosine, compositions, kit et procede pour le traitement d'affections des voies aeriennes associees a la bronchoconstriction, a l'inflammation pulmonaire, aux allergies et a la depletion de surfactant - Google Patents
Oligonucleotide antisens a faible teneur en adenosine, compositions, kit et procede pour le traitement d'affections des voies aeriennes associees a la bronchoconstriction, a l'inflammation pulmonaire, aux allergies et a la depletion de surfactant Download PDFInfo
- Publication number
- WO2000062736A3 WO2000062736A3 PCT/US2000/008020 US0008020W WO0062736A3 WO 2000062736 A3 WO2000062736 A3 WO 2000062736A3 US 0008020 W US0008020 W US 0008020W WO 0062736 A3 WO0062736 A3 WO 0062736A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antisense
- bronchoconstriction
- target gene
- adenosine
- ies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14005400A IL140054A0 (en) | 1999-04-06 | 2000-03-24 | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion |
JP2000611873A JP2003515525A (ja) | 1999-04-06 | 2000-03-24 | 気管支収縮、肺炎、アレルギーおよびサーファクタント枯渇と関連する気道障害を治療するための、低アデノシンアンチセンスオリゴヌクレオチド、その組成物、キットならびにその方法 |
CA002330022A CA2330022A1 (fr) | 1999-04-06 | 2000-03-24 | Oligonucleotide antisens a faible teneur en adenosine, compositions, kit et procede pour le traitement d'affections des voies aeriennes associees a la bronchoconstriction, a l'inflammation pulmonaire, aux allergies et a la depletion de surfactant |
BR0006019-4A BR0006019A (pt) | 1999-04-06 | 2000-03-24 | Oligonucleotìdeo de anti-sentido de adenosina baixo, composições, kit & método para tratamento de distúrbios de vias aéreas associados com broncoconstricção, inflamação pulmonar, alergia(s) & depleção de surfactante |
EP00919668A EP1168919A4 (fr) | 1999-04-06 | 2000-03-24 | Oligonucleotide antisens a faible teneur en adenosine, compositions, kit et procede pour le traitement d'affections des voies aeriennes associees a la bronchoconstriction, a l'inflammation pulmonaire, aux allergies et a la depletion de surfactant |
AU40317/00A AU4031700A (en) | 1999-04-06 | 2000-03-24 | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion |
HK02102615.9A HK1042017A1 (zh) | 1999-04-06 | 2002-04-08 | 低腺苷反義寡核苷酸、組合物、試劑盒及與支氣管緊縮、肺炎、過敏及表面活性劑缺失相關的通氣途徑疾病的治療方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12795899P | 1999-04-06 | 1999-04-06 | |
US60/127,958 | 1999-04-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000062736A2 WO2000062736A2 (fr) | 2000-10-26 |
WO2000062736A3 true WO2000062736A3 (fr) | 2001-10-11 |
Family
ID=22432865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/008020 WO2000062736A2 (fr) | 1999-04-06 | 2000-03-24 | Oligonucleotide antisens a faible teneur en adenosine, compositions, kit et procede pour le traitement d'affections des voies aeriennes associees a la bronchoconstriction, a l'inflammation pulmonaire, aux allergies et a la depletion de surfactant |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1168919A4 (fr) |
JP (1) | JP2003515525A (fr) |
CN (1) | CN1330513A (fr) |
AU (1) | AU4031700A (fr) |
BR (1) | BR0006019A (fr) |
CA (1) | CA2330022A1 (fr) |
HK (1) | HK1042017A1 (fr) |
IL (1) | IL140054A0 (fr) |
WO (1) | WO2000062736A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737040B1 (en) | 1998-08-04 | 2004-05-18 | Diadexus, Inc. | Method and antibody for imaging breast cancer |
US6730477B1 (en) | 1998-08-04 | 2004-05-04 | Diadexus, Inc. | Method of diagnosing, monitoring and staging breast cancer |
JP2002539831A (ja) * | 1999-03-26 | 2002-11-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 47個のヒト分泌タンパク質 |
DE10049549A1 (de) * | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
DE60225141T2 (de) | 2001-07-06 | 2009-03-05 | Topigen Pharmaceuticals Inc., Montreal | Verfahren zur erhöhung der in vivo wirksamkeit von oligonukleotiden und zur entzündungshemmung in säugetieren |
WO2004086052A2 (fr) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Produits de diagnostic et de therapeutique pour des maladies liees au recepteur de l'adenosine a2b couple a la proteine g (adora2b) |
US7671182B2 (en) * | 2003-03-31 | 2010-03-02 | Council Of Scientific & Industrial Research | Gene variants of signal transducer and activator of transcription-6 (STAT 6) variants and process of detection the same |
EP2314689A3 (fr) * | 2003-12-03 | 2012-12-19 | Coda Therapeutics (NZ) Ltd | Composés anti-sens ciblés contre les connexines et procédés d'utilisation associés |
WO2006010492A1 (fr) * | 2004-07-28 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics et therapeutiques pour des maladies associees a tryptase 1 (tps1) |
US8673268B2 (en) | 2004-10-15 | 2014-03-18 | Galapagos N.V. | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
US7485468B2 (en) | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
ES2392449T3 (es) * | 2004-10-20 | 2012-12-10 | Antisense Therapeutics Ltd | Modulación antisentido de la expresión de la integrina alfa-4 |
BRPI0517387A8 (pt) | 2004-10-29 | 2017-07-11 | Topigen Pharmaceuticals Inc | Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas |
MX2007005866A (es) | 2004-11-17 | 2007-11-12 | Amgen Inc | Anticuerpos monoclonales totalmente humanos para il-13. |
US8592384B2 (en) | 2005-04-04 | 2013-11-26 | The Board Of Regents Of The University Of Texas System | Micro-RNA's that regulate muscle cells |
CA3177366A1 (fr) * | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Therapie locale de troubles inflammatoires des voies aeriennes inferieures avec des inhibiteurs de cytokine proinflammatoire |
US8426581B2 (en) * | 2009-03-27 | 2013-04-23 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of the FCεR1α gene |
WO2014170497A2 (fr) * | 2013-04-19 | 2014-10-23 | Epiontis Gmbh | Méthode d'identification de la composition cellulaire quantitative d'un échantillon biologique |
AU2019347849A1 (en) * | 2018-09-26 | 2021-05-20 | AUM LifeTech, Inc. | 2'FANA modified Foxp3 antisense oligonucleotides and methods of use thereof |
CN109260217A (zh) * | 2018-09-30 | 2019-01-25 | 深圳松乐生物科技有限公司 | 3`-脱氧次黄嘌呤核苷在制备用于多种疾病药品、食品或保健品中的应用 |
CN114591963B (zh) * | 2022-05-10 | 2022-07-19 | 上海优替济生生物医药有限公司 | sgRNA及利用其构建GM-CSF(-)细胞的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
WO1999011275A2 (fr) * | 1997-09-05 | 1999-03-11 | The Regents Of The University Of California | Utilisation d'oligonucleotides immunostimulants pour la prevention ou la reduction des inflammations a mediation granulocytaire et stimulees par des antigenes |
US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
US6017898A (en) * | 1995-11-21 | 2000-01-25 | Icn Pharmaceuticals, Inc. | Inhibition of tumor growth by antisense oligonucleotides for IL-8 and IL-8 receptor |
US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3739785B2 (ja) * | 1991-11-26 | 2006-01-25 | アイシス ファーマシューティカルズ,インコーポレイティド | 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形 |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5320962A (en) * | 1992-07-22 | 1994-06-14 | Duke University | DNA encoding the human A1 adenosine receptor |
US6040296A (en) * | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
EP1080225A4 (fr) * | 1998-05-21 | 2004-02-04 | Isis Pharmaceuticals Inc | Compositions et methodes d'administration aux poumons d'acides nucleiques |
WO2000009525A2 (fr) * | 1998-08-03 | 2000-02-24 | East Carolina University | Agent comprenant des oligonucleotides antisens a faible teneur en adenosine, composition, trousse et traitements |
-
2000
- 2000-03-24 JP JP2000611873A patent/JP2003515525A/ja not_active Withdrawn
- 2000-03-24 EP EP00919668A patent/EP1168919A4/fr not_active Ceased
- 2000-03-24 IL IL14005400A patent/IL140054A0/xx unknown
- 2000-03-24 AU AU40317/00A patent/AU4031700A/en not_active Abandoned
- 2000-03-24 CA CA002330022A patent/CA2330022A1/fr not_active Abandoned
- 2000-03-24 CN CN00801046A patent/CN1330513A/zh active Pending
- 2000-03-24 WO PCT/US2000/008020 patent/WO2000062736A2/fr not_active Application Discontinuation
- 2000-03-24 BR BR0006019-4A patent/BR0006019A/pt not_active IP Right Cessation
-
2002
- 2002-04-08 HK HK02102615.9A patent/HK1042017A1/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
US6017898A (en) * | 1995-11-21 | 2000-01-25 | Icn Pharmaceuticals, Inc. | Inhibition of tumor growth by antisense oligonucleotides for IL-8 and IL-8 receptor |
WO1999011275A2 (fr) * | 1997-09-05 | 1999-03-11 | The Regents Of The University Of California | Utilisation d'oligonucleotides immunostimulants pour la prevention ou la reduction des inflammations a mediation granulocytaire et stimulees par des antigenes |
Non-Patent Citations (5)
Title |
---|
AGRAWAL S, ET AL.: "ANTISENSE RESEARCH AND APPLICATION", ANTISENSE RESEARCH AND APPLICATION, SPRINGER VERLAG, BERLIN, DE, 1 July 1998 (1998-07-01), DE, pages 01A/01B + 01 - 50, XP002929186 * |
NYCE ET AL.: "DNA antisense therapy for asthma in an animal model", NATURE,, vol. 274, February 1997 (1997-02-01), pages 721 - 724, XP002929187 * |
NYCE J.W.: "Insight into adenosine receptor function using antisense and gene-knockout approaches", TRENDS IN PHARMACOLOGICAL SCIENCES,, vol. 20, no. 2, February 1999 (1999-02-01), pages 79 - 83, XP002929189 * |
RICHARDSON P.J.: "Blocking adenosine with antisense", NATURE,, vol. 385, February 1997 (1997-02-01), pages 684 - 685, XP002929188 * |
SANGHVI Y S: "HETEROCYCLIC BASE MODIFICATIONS IN NUCLEIC ACIDS AND THEIR APPLICATIONS IN ANTISENSE OLIGONUCLEOTIDES", ANTISENSE RESEARCH AND APPLICATION, SPRINGER VERLAG, BERLIN, DE, 1 January 1993 (1993-01-01), DE, pages 273 - 286, XP002929185 * |
Also Published As
Publication number | Publication date |
---|---|
CN1330513A (zh) | 2002-01-09 |
AU4031700A (en) | 2000-11-02 |
HK1042017A1 (zh) | 2002-08-02 |
BR0006019A (pt) | 2001-03-13 |
WO2000062736A2 (fr) | 2000-10-26 |
IL140054A0 (en) | 2002-02-10 |
JP2003515525A (ja) | 2003-05-07 |
EP1168919A4 (fr) | 2002-03-06 |
CA2330022A1 (fr) | 2000-10-26 |
EP1168919A2 (fr) | 2002-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000062736A3 (fr) | Oligonucleotide antisens a faible teneur en adenosine, compositions, kit et procede pour le traitement d'affections des voies aeriennes associees a la bronchoconstriction, a l'inflammation pulmonaire, aux allergies et a la depletion de surfactant | |
EP0946201A4 (fr) | Agent et methode de traitement de maladies et d'etats pathologiques associes a des malaises respiratoires et a une inflammation pulmonaire | |
WO2002085308A3 (fr) | Compositions, formulations et trousses contenant des oligonucleotides anti-sens et des steroides anti-inflammatoires et/ou un ubiquinone pour le traitement de maladies respiratoires ou pulmonaires | |
AU2002256873A1 (en) | Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof | |
WO2005063297A3 (fr) | Polytherapie a base de melatonine destinee a ameliorer la qualite du sommeil | |
WO2005094899A8 (fr) | Traitement de cancers par un antisens anti-clusterine | |
WO2000049937A3 (fr) | Therapie anti-sens a message de regression prostatique par la testosterone (trpm-2) | |
CN110799647A (zh) | 双尾自递送sirna及相关的方法 | |
BR9915095A (pt) | Composição farmacêutica ministrável em aerosol | |
AU6808001A (en) | Glutamic acid decarboxylase (gad) based delivery systems | |
WO2004105702A3 (fr) | Compositions pharmaceutiques expansibles et procedes de traitement d'un trouble donne | |
WO1998002190A3 (fr) | Complexes adn/amphiphiles cationiques | |
JP2010229143A (ja) | オリゴヌクレオチド含有薬理学的組成物およびその使用 | |
EP1463530A4 (fr) | Administration de gdnf induite par le virus adeno-associe dans des muscles du squelette | |
IL211288A (en) | Medical vaginal preparations to reduce or relieve uterine rhythm, and use of anti-arrhythmic therapy in the preparation of vaginal drugs to reduce or relieve uterine rhythm | |
WO2004030660A3 (fr) | Compositions et procedes pour le traitement du cancer de la prostate et d'autres types de cancer | |
WO2005055948A3 (fr) | Epha2, epha4 et lmw-ptp et procedes de traitement de maladies cellulaires hyperproliferatives | |
EP3431604A1 (fr) | Compositions organiques pour traiter des maladies associées à bêta-enac | |
RU2019111715A (ru) | Окисляющие аммиак микроорганизмы для применения и доставки в интраназальной системе | |
WO2004108088A3 (fr) | Procedes et compositions pour la therapie a l'interferon | |
TNSN04235A1 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
WO2003074561A8 (fr) | Methode de traitement d'une maladie allergique et de l'asthme par transfert du gene ifn-$g(g) medie par un adenovirus et un virus adeno-associe recombinants | |
WO2003049667A3 (fr) | Methode de traitement du cancer | |
CA2421087A1 (fr) | Oligodesoxynucleotides antisens, proteines de fixation du facteur de croissance insulinoide 2 (igfbp-2) pour le traitement du cancer de la prostate et d'autres tumeurs endocrines | |
CN111956667A (zh) | 多功能干细胞外泌体和间充质干细胞裂解物在制备治疗过敏性鼻炎药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00801046.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000919668 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2330022 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 140054 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/012093 Country of ref document: MX Ref document number: 1020007013847 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2000919668 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007013847 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 2000919668 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000919668 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007013847 Country of ref document: KR |